What is inter partes review and why does it matter?
By Nicole Longo | March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...
Read More
Supporting opportunities for enhanced competition in the marketplace
By Andrew Powaleny | November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...
Read More
Biopharma leads sustained economic growth driven by IP-intensive industries
By Tim McClung | September 26, 2017
While the biopharmaceutical industry is the global leader in generating innovative medicines and technologies, lesser known is the industry’s central role in sustaining economic growth. A recent...
Read More
Opportunities to build upon enhanced competition for medicines in the marketplace
By David Korn | July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...
Read More
Guest Post: Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey
By Guest Contributor | July 24, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority
By Mark Grayson | June 13, 2017
Yesterday, PhRMA filed comments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration’s review of our trading relationship with...
Read More
Foreign government price setting by any name harms innovation and access to medicines
By Kevin Haninger | June 6, 2017
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below the value they provide to patients, health care systems, and the...
Read More
Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation
By Jay Taylor | May 23, 2017
In the latest publication of its annual Special 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges...
Read More
Compulsory licensing: A misused and abused international trade law
By Jay Taylor | May 16, 2017
To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing...
Read More
It’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any...
Read More
Medicare Monday (100)
340B Spotlight (33)
Cost & Consequence (0)
